ArticleClinical pharmacokinetics2025

Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer.

Stephanie Kong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.